bluebird bio Joins the NASDAQ Biotechnology Index Read more about bluebird bio Joins the NASDAQ Biotechnology Index
bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia Read more about bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
bluebird bio to Present at Deutsche Bank BioFEST Conference Read more about bluebird bio to Present at Deutsche Bank BioFEST Conference
bluebird bio Reports Fiscal Third Quarter 2013 Financial Results Read more about bluebird bio Reports Fiscal Third Quarter 2013 Financial Results
bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD Read more about bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD
bluebird bio Joins the Russell 2000® Index Read more about bluebird bio Joins the Russell 2000® Index
Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy Read more about Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy
bluebird bio to Present at Morgan Stanley Global Healthcare Conference Read more about bluebird bio to Present at Morgan Stanley Global Healthcare Conference
bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum Read more about bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum
bluebird bio Reports Fiscal Second Quarter 2013 Financial Results Read more about bluebird bio Reports Fiscal Second Quarter 2013 Financial Results